KRAS and BRAF mutations predict primary resistance to imatinib in gastrointestinal stromal tumors

Claudia Miranda, Martina Nucifora, Francesca Molinari, Elena Conca, Maria Chiara Anania, Andrea Bordoni, Piercarlo Saletti, Luca Mazzucchelli, Silvana Pilotti, Marco A. Pierotti, Elena Tamborini, Angela Greco, Milo Frattini

Research output: Contribution to journalArticle

104 Citations (Scopus)

Abstract

Purpose: Gastrointestinal stromal tumors (GIST) are characterized by gain-of-function mutations in KIT/ PDGFRA genes leading to a constitutive receptor activation which is well counteracted by imatinib. However, cases in which imatinib as first-line treatment has no effects are reported (primary resistance). Our purpose is to investigate alterations in downstream effectors, not reported so far in mutated GIST, possibly explaining the primary resistance to targeted treatments. Experimental Design:Twoindependent naive GIST cohorts have been analyzed for KIT,PDGFRA, KRAS, and BRAF mutations by direct sequencing. Cell lines expressing a constitutively activated and imatinibresponding KIT, alone or in combination with activated KRAS and BRAF, were produced and treated with imatinib. KIT receptor and its downstream effectors were analyzed by direct Western blotting. Results: In naive GISTs carrying activating mutations in KIT or PDGFRA a concomitant activating mutation was detected in KRAS (5%) or BRAF (about 2%) genes. In vitro experiments showed that imatinib was able to switch off the mutated receptor KIT but not the downstream signaling triggered by RAS-RAF effectors. Conclusions: These data suggest the activation of mitogen-activated protein kinase pathway as a possible novel mechanism of primary resistance to imatinib in GISTs and could explain the survival curves obtained from several clinical studies where 2% to 4% of patients with GIST treated with imatinib, despite carrying KIT-sensitive mutations, do not respond to the treatment.

Original languageEnglish
Pages (from-to)1769-1776
Number of pages8
JournalClinical Cancer Research
Volume18
Issue number6
DOIs
Publication statusPublished - Mar 15 2012

Fingerprint

Gastrointestinal Stromal Tumors
Mutation
Mitogen-Activated Protein Kinases
Genes
Imatinib Mesylate
Research Design
Therapeutics
Western Blotting
Cell Line
Survival

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Miranda, C., Nucifora, M., Molinari, F., Conca, E., Anania, M. C., Bordoni, A., ... Frattini, M. (2012). KRAS and BRAF mutations predict primary resistance to imatinib in gastrointestinal stromal tumors. Clinical Cancer Research, 18(6), 1769-1776. https://doi.org/10.1158/1078-0432.CCR-11-2230

KRAS and BRAF mutations predict primary resistance to imatinib in gastrointestinal stromal tumors. / Miranda, Claudia; Nucifora, Martina; Molinari, Francesca; Conca, Elena; Anania, Maria Chiara; Bordoni, Andrea; Saletti, Piercarlo; Mazzucchelli, Luca; Pilotti, Silvana; Pierotti, Marco A.; Tamborini, Elena; Greco, Angela; Frattini, Milo.

In: Clinical Cancer Research, Vol. 18, No. 6, 15.03.2012, p. 1769-1776.

Research output: Contribution to journalArticle

Miranda, C, Nucifora, M, Molinari, F, Conca, E, Anania, MC, Bordoni, A, Saletti, P, Mazzucchelli, L, Pilotti, S, Pierotti, MA, Tamborini, E, Greco, A & Frattini, M 2012, 'KRAS and BRAF mutations predict primary resistance to imatinib in gastrointestinal stromal tumors', Clinical Cancer Research, vol. 18, no. 6, pp. 1769-1776. https://doi.org/10.1158/1078-0432.CCR-11-2230
Miranda, Claudia ; Nucifora, Martina ; Molinari, Francesca ; Conca, Elena ; Anania, Maria Chiara ; Bordoni, Andrea ; Saletti, Piercarlo ; Mazzucchelli, Luca ; Pilotti, Silvana ; Pierotti, Marco A. ; Tamborini, Elena ; Greco, Angela ; Frattini, Milo. / KRAS and BRAF mutations predict primary resistance to imatinib in gastrointestinal stromal tumors. In: Clinical Cancer Research. 2012 ; Vol. 18, No. 6. pp. 1769-1776.
@article{a58efb42c56647f59bb32816f786524a,
title = "KRAS and BRAF mutations predict primary resistance to imatinib in gastrointestinal stromal tumors",
abstract = "Purpose: Gastrointestinal stromal tumors (GIST) are characterized by gain-of-function mutations in KIT/ PDGFRA genes leading to a constitutive receptor activation which is well counteracted by imatinib. However, cases in which imatinib as first-line treatment has no effects are reported (primary resistance). Our purpose is to investigate alterations in downstream effectors, not reported so far in mutated GIST, possibly explaining the primary resistance to targeted treatments. Experimental Design:Twoindependent naive GIST cohorts have been analyzed for KIT,PDGFRA, KRAS, and BRAF mutations by direct sequencing. Cell lines expressing a constitutively activated and imatinibresponding KIT, alone or in combination with activated KRAS and BRAF, were produced and treated with imatinib. KIT receptor and its downstream effectors were analyzed by direct Western blotting. Results: In naive GISTs carrying activating mutations in KIT or PDGFRA a concomitant activating mutation was detected in KRAS (5{\%}) or BRAF (about 2{\%}) genes. In vitro experiments showed that imatinib was able to switch off the mutated receptor KIT but not the downstream signaling triggered by RAS-RAF effectors. Conclusions: These data suggest the activation of mitogen-activated protein kinase pathway as a possible novel mechanism of primary resistance to imatinib in GISTs and could explain the survival curves obtained from several clinical studies where 2{\%} to 4{\%} of patients with GIST treated with imatinib, despite carrying KIT-sensitive mutations, do not respond to the treatment.",
author = "Claudia Miranda and Martina Nucifora and Francesca Molinari and Elena Conca and Anania, {Maria Chiara} and Andrea Bordoni and Piercarlo Saletti and Luca Mazzucchelli and Silvana Pilotti and Pierotti, {Marco A.} and Elena Tamborini and Angela Greco and Milo Frattini",
year = "2012",
month = "3",
day = "15",
doi = "10.1158/1078-0432.CCR-11-2230",
language = "English",
volume = "18",
pages = "1769--1776",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "6",

}

TY - JOUR

T1 - KRAS and BRAF mutations predict primary resistance to imatinib in gastrointestinal stromal tumors

AU - Miranda, Claudia

AU - Nucifora, Martina

AU - Molinari, Francesca

AU - Conca, Elena

AU - Anania, Maria Chiara

AU - Bordoni, Andrea

AU - Saletti, Piercarlo

AU - Mazzucchelli, Luca

AU - Pilotti, Silvana

AU - Pierotti, Marco A.

AU - Tamborini, Elena

AU - Greco, Angela

AU - Frattini, Milo

PY - 2012/3/15

Y1 - 2012/3/15

N2 - Purpose: Gastrointestinal stromal tumors (GIST) are characterized by gain-of-function mutations in KIT/ PDGFRA genes leading to a constitutive receptor activation which is well counteracted by imatinib. However, cases in which imatinib as first-line treatment has no effects are reported (primary resistance). Our purpose is to investigate alterations in downstream effectors, not reported so far in mutated GIST, possibly explaining the primary resistance to targeted treatments. Experimental Design:Twoindependent naive GIST cohorts have been analyzed for KIT,PDGFRA, KRAS, and BRAF mutations by direct sequencing. Cell lines expressing a constitutively activated and imatinibresponding KIT, alone or in combination with activated KRAS and BRAF, were produced and treated with imatinib. KIT receptor and its downstream effectors were analyzed by direct Western blotting. Results: In naive GISTs carrying activating mutations in KIT or PDGFRA a concomitant activating mutation was detected in KRAS (5%) or BRAF (about 2%) genes. In vitro experiments showed that imatinib was able to switch off the mutated receptor KIT but not the downstream signaling triggered by RAS-RAF effectors. Conclusions: These data suggest the activation of mitogen-activated protein kinase pathway as a possible novel mechanism of primary resistance to imatinib in GISTs and could explain the survival curves obtained from several clinical studies where 2% to 4% of patients with GIST treated with imatinib, despite carrying KIT-sensitive mutations, do not respond to the treatment.

AB - Purpose: Gastrointestinal stromal tumors (GIST) are characterized by gain-of-function mutations in KIT/ PDGFRA genes leading to a constitutive receptor activation which is well counteracted by imatinib. However, cases in which imatinib as first-line treatment has no effects are reported (primary resistance). Our purpose is to investigate alterations in downstream effectors, not reported so far in mutated GIST, possibly explaining the primary resistance to targeted treatments. Experimental Design:Twoindependent naive GIST cohorts have been analyzed for KIT,PDGFRA, KRAS, and BRAF mutations by direct sequencing. Cell lines expressing a constitutively activated and imatinibresponding KIT, alone or in combination with activated KRAS and BRAF, were produced and treated with imatinib. KIT receptor and its downstream effectors were analyzed by direct Western blotting. Results: In naive GISTs carrying activating mutations in KIT or PDGFRA a concomitant activating mutation was detected in KRAS (5%) or BRAF (about 2%) genes. In vitro experiments showed that imatinib was able to switch off the mutated receptor KIT but not the downstream signaling triggered by RAS-RAF effectors. Conclusions: These data suggest the activation of mitogen-activated protein kinase pathway as a possible novel mechanism of primary resistance to imatinib in GISTs and could explain the survival curves obtained from several clinical studies where 2% to 4% of patients with GIST treated with imatinib, despite carrying KIT-sensitive mutations, do not respond to the treatment.

UR - http://www.scopus.com/inward/record.url?scp=84858179982&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84858179982&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-11-2230

DO - 10.1158/1078-0432.CCR-11-2230

M3 - Article

VL - 18

SP - 1769

EP - 1776

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 6

ER -